Buscar
Immuron Ltd
IMRNAñadir a la lista de seguimiento
1.090USD
-0.020-1.80%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
6.38MCap. mercado
PérdidaP/E TTM
Más Datos de Immuron Ltd Compañía
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.
Información de Immuron Ltd
Símbolo de cotizaciónIMRN
Nombre de la empresaImmuron Ltd
Fecha de salida a bolsaApr 30, 1999
Director ejecutivoLydeamore (Steven)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalApr 30
Dirección62 Lygon Street
Ciudad
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal3053
Teléfono61398245254
Sitio Webhttps://www.immuron.com.au
Símbolo de cotizaciónIMRN
Fecha de salida a bolsaApr 30, 1999
Director ejecutivoLydeamore (Steven)
Ejecutivos de Immuron Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Daniel Pollock
Mr. Daniel Pollock
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Phillip Hains
Mr. Phillip Hains
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Dr. Jerry Kanellos, Ph.D.
Dr. Jerry Kanellos, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Prof. Ravi Savarirayan
Prof. Ravi Savarirayan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Brennan
Mr. Paul Brennan
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Steven Lydeamore
Mr. Steven Lydeamore
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Jeannette (Jeannie) Joughin
Dr. Jeannette (Jeannie) Joughin
Non-Executive Director
Non-Executive Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Daniel Pollock
Mr. Daniel Pollock
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Phillip Hains
Mr. Phillip Hains
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Dr. Jerry Kanellos, Ph.D.
Dr. Jerry Kanellos, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Prof. Ravi Savarirayan
Prof. Ravi Savarirayan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Brennan
Mr. Paul Brennan
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Steven Lydeamore
Mr. Steven Lydeamore
Chief Executive Officer
Chief Executive Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Immuron Ltd?
Los cinco principales accionistas de Immuron Ltd son: Mr. Daniel Pollock
¿Cuántas instituciones poseen acciones de Immuron Ltd (IMRN)?
A fecha de 2026Q1, 15 instituciones poseen acciones de Immuron Ltd, con un valor de mercado combinado de aproximadamente 160.30K, lo que representa el 1.96% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 54807.00.
¿Cuál es la mayor fuente de ganancias de Immuron Ltd?
El 2026Q1, el segmento empresarial Travelan generó la ganancia más alta para Immuron Ltd, ascendiendo a 1.74M y representando el 96.68% de la ganancia total.